{"pmid":32354666,"pmcid":"PMC7180362","title":"Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.","text":["Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.","Arch Cardiovasc Dis","Sacher, Frederic","Fauchier, Laurent","Boveda, Serge","de Chillou, Christian","Defaye, Pascal","Deharo, Jean Claude","Gandjbakhch, Estelle","Probst, Vincent","Cohen, Ariel","Leclercq, Christophe","32354666"],"journal":"Arch Cardiovasc Dis","authors":["Sacher, Frederic","Fauchier, Laurent","Boveda, Serge","de Chillou, Christian","Defaye, Pascal","Deharo, Jean Claude","Gandjbakhch, Estelle","Probst, Vincent","Cohen, Ariel","Leclercq, Christophe"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354666","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.acvd.2020.04.003","keywords":["covid-19","covid-19","ecg","hydroxychloroquine","long qt","qt long medicamenteux","qt prolonging drugs","sars-cov-2","torsades de pointe"],"topics":["Treatment"],"weight":1,"_version_":1666138495246139392,"score":9.490897,"similar":[{"pmid":32479900,"title":"Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.","text":["Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.","BACKGROUND: Early during the current COVID-19 pandemic, hydroxychloroquine (HCQ) received a significant amount of attention as a potential antiviral treatment, such that it became one of the most commonly prescribed medications for COVID-19 patients. However, not only the effectiveness of HCQ has remained questionable, and mainly based on pre-clinical, and a few small clinical studies, but also HCQ is known to be potentially arrhythmogenic, especially as a result of QT prolongation. OBJECTIVE: To investigate the arrhythmic effects of HCQ as the heightened risk is especially relevant as COVID-19 patients are at a higher risk of cardiac complications and arrhythmias at baseline. METHODS: Here, we use the optical mapping technique, using voltage-sensitive fluorescent dyes, to illustrate the arrhythmic effects of hydroxychloroquine in ex-vivo guinea pig and rabbit hearts perfused with the upper therapeutic serum doses of HCQ (up to 1000ng/ml). RESULTS: We observe that HCQ markedly increases the action potential dispersion and results in the development of repolarization alternans and initiate polymorphic ventricular tachycardia. CONCLUSIONS: These results further highlight the proarrhythmic effects of HCQ.","Heart Rhythm","Uzelac, Ilija","Iravanian, Shahriar","Ashikaga, Hiroshi","Bhatia, Neal K","Herndon, Conner","Kaboudian, Abouzar","Gumbart, James C","Cherry, Elizabeth M","Fenton, Flavio H","32479900"],"abstract":["BACKGROUND: Early during the current COVID-19 pandemic, hydroxychloroquine (HCQ) received a significant amount of attention as a potential antiviral treatment, such that it became one of the most commonly prescribed medications for COVID-19 patients. However, not only the effectiveness of HCQ has remained questionable, and mainly based on pre-clinical, and a few small clinical studies, but also HCQ is known to be potentially arrhythmogenic, especially as a result of QT prolongation. OBJECTIVE: To investigate the arrhythmic effects of HCQ as the heightened risk is especially relevant as COVID-19 patients are at a higher risk of cardiac complications and arrhythmias at baseline. METHODS: Here, we use the optical mapping technique, using voltage-sensitive fluorescent dyes, to illustrate the arrhythmic effects of hydroxychloroquine in ex-vivo guinea pig and rabbit hearts perfused with the upper therapeutic serum doses of HCQ (up to 1000ng/ml). RESULTS: We observe that HCQ markedly increases the action potential dispersion and results in the development of repolarization alternans and initiate polymorphic ventricular tachycardia. CONCLUSIONS: These results further highlight the proarrhythmic effects of HCQ."],"journal":"Heart Rhythm","authors":["Uzelac, Ilija","Iravanian, Shahriar","Ashikaga, Hiroshi","Bhatia, Neal K","Herndon, Conner","Kaboudian, Abouzar","Gumbart, James C","Cherry, Elizabeth M","Fenton, Flavio H"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479900","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.hrthm.2020.05.030","keywords":["apd dispersion","arrhythmias","t wave alternans","alternans","experimental optical mapping","hydroxychloroquine","long qt"],"topics":["Treatment"],"weight":1,"_version_":1668437835026268160,"score":62.684864},{"pmid":32387247,"title":"ENHANCED ECG MONITORING OF COVID-19 PATIENTS.","text":["ENHANCED ECG MONITORING OF COVID-19 PATIENTS.","BACKGROUND: Many of the drugs being used in the treatment of the ongoing pandemic coronavirus disease 2019 (COVID-19) are associated with QT prolongation. Expert guidance supports ECG monitoring to optimize patient safety. OBJECTIVE: To establish an enhanced process for ECG monitoring of patients being treated for COVID-19. METHODS: We created an SBAR (Situation Background Assessment Recommendation Tool) identifying the indication for ECGs in COVID-19 patients, and tagged these ECGs to ensure prompt over reading and identification of those with QT prolongation (QTc >470 ms for QRS < 120 ms, QTc > 500 ms for QRS > 120 ms). This triggered a phone call from the electrophysiology service to the primary team to provide management guidance and a formal consultation if requested. RESULTS: During a 2-week period we reviewed 2006 ECGs, corresponding to 524 unique patients, of whom 103 (19.7%) met SBAR defined criteria for QT prolongation. When compared to those without QT prolongation, these patients were more often in the intensive care unit (58.3% vs 35.4%) and more likely to be intubated (31.1 vs 18.1%). Fifty patients with QT prolongation (48.5%) had electrolyte abnormalities, 98 (95.1%) were on COVID-19 related QT prolonging medications, and 62 (60.2%) were on 1-4 additional non COVID-19 related QT prolonging drugs. Electrophysiology recommendations were given to limit modifiable risk factors. No patient developed torsade de pointes. CONCLUSION: This process functioned efficiently, identified a high percentage of patients with QT prolongation, and led to relevant interventions. Arrhythmias were rare. No patient developed torsade de pointes.","Heart Rhythm","Jain, Shashank","Workman, Virginia","Ganeshan, Raj","Obasare, Edinrin R","Burr, Alicia","DeBiasi, Ralph M","Freeman, James V","Akar, Joseph","Lampert, Rachel","Rosenfeld, Lynda E","32387247"],"abstract":["BACKGROUND: Many of the drugs being used in the treatment of the ongoing pandemic coronavirus disease 2019 (COVID-19) are associated with QT prolongation. Expert guidance supports ECG monitoring to optimize patient safety. OBJECTIVE: To establish an enhanced process for ECG monitoring of patients being treated for COVID-19. METHODS: We created an SBAR (Situation Background Assessment Recommendation Tool) identifying the indication for ECGs in COVID-19 patients, and tagged these ECGs to ensure prompt over reading and identification of those with QT prolongation (QTc >470 ms for QRS < 120 ms, QTc > 500 ms for QRS > 120 ms). This triggered a phone call from the electrophysiology service to the primary team to provide management guidance and a formal consultation if requested. RESULTS: During a 2-week period we reviewed 2006 ECGs, corresponding to 524 unique patients, of whom 103 (19.7%) met SBAR defined criteria for QT prolongation. When compared to those without QT prolongation, these patients were more often in the intensive care unit (58.3% vs 35.4%) and more likely to be intubated (31.1 vs 18.1%). Fifty patients with QT prolongation (48.5%) had electrolyte abnormalities, 98 (95.1%) were on COVID-19 related QT prolonging medications, and 62 (60.2%) were on 1-4 additional non COVID-19 related QT prolonging drugs. Electrophysiology recommendations were given to limit modifiable risk factors. No patient developed torsade de pointes. CONCLUSION: This process functioned efficiently, identified a high percentage of patients with QT prolongation, and led to relevant interventions. Arrhythmias were rare. No patient developed torsade de pointes."],"journal":"Heart Rhythm","authors":["Jain, Shashank","Workman, Virginia","Ganeshan, Raj","Obasare, Edinrin R","Burr, Alicia","DeBiasi, Ralph M","Freeman, James V","Akar, Joseph","Lampert, Rachel","Rosenfeld, Lynda E"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387247","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.hrthm.2020.04.047","keywords":["covid-19","ecg","hydroxychloroquine","qt prolongation","torsade de pointe"],"topics":["Treatment"],"weight":1,"_version_":1666428892696543232,"score":61.35253},{"pmid":32363145,"pmcid":"PMC7195299","title":"An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.","text":["An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.","HeartRhythm Case Rep","Mitra, Raman L","Greenstein, Steven A","Epstein, Laurence M","32363145"],"journal":"HeartRhythm Case Rep","authors":["Mitra, Raman L","Greenstein, Steven A","Epstein, Laurence M"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363145","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.hrcr.2020.03.016","keywords":["acquired lqts","azithromycin","covid-19","chloroquine","drug toxicity","flow chart","hydroxychloroquine","long qt","pandemic","proarrhythmia","torsades de pointes","ventricular fibrillation"],"e_drugs":["Hydroxychloroquine","Chloroquine","Azithromycin","Lidocaine"],"topics":["Case Report"],"weight":1,"_version_":1666138496012648448,"score":58.18133},{"pmid":32449420,"title":"Interpretation of arrhythmogenic effects of COVID-19 disease through ECG.","text":["Interpretation of arrhythmogenic effects of COVID-19 disease through ECG.","Objective: We aimed to detect the malignant arrhythmic potential of COVID-19 with surface electrocardiographic (ECG) markers.Material and method: Of the ECG parameters PR, QT, QTc, QTd, TPe, and Tpe/QTc were measured in 51 COVID-19 patients and 40 in control subjects.Results: Compared to control group mean QTc (410.8 +/- 24.3 msec vs. 394.6 +/- 20.3 msec, p < .001) and Tpe/QTc (0.19 +/- 0.02 vs. 0.18 +/- 0.04, p = .036) and median QTd (47.52 vs. 46.5) values were significantly higher in COVID-19 patients. Troponin levels were significantly correlated with heart rate (r = 0.387, p = .006) but not with ECG parameters.Conclusion: Several ventricular arrhythmia surface ECG predictors including QTc, QTd, and Tpe/QTc are increased in COVID-19 patients. Since medications used in COVID-19 patients have the potential to affect these parameters, giving importance to these ECG markers may have a significant contribution in decreasing disease-related arrhythmias.","Aging Male","Ozturk, Fatih","Karaduman, Medeni","Coldur, Rabia","Incecik, Saban","Gunes, Yilmaz","Tuncer, Mustafa","32449420"],"abstract":["Objective: We aimed to detect the malignant arrhythmic potential of COVID-19 with surface electrocardiographic (ECG) markers.Material and method: Of the ECG parameters PR, QT, QTc, QTd, TPe, and Tpe/QTc were measured in 51 COVID-19 patients and 40 in control subjects.Results: Compared to control group mean QTc (410.8 +/- 24.3 msec vs. 394.6 +/- 20.3 msec, p < .001) and Tpe/QTc (0.19 +/- 0.02 vs. 0.18 +/- 0.04, p = .036) and median QTd (47.52 vs. 46.5) values were significantly higher in COVID-19 patients. Troponin levels were significantly correlated with heart rate (r = 0.387, p = .006) but not with ECG parameters.Conclusion: Several ventricular arrhythmia surface ECG predictors including QTc, QTd, and Tpe/QTc are increased in COVID-19 patients. Since medications used in COVID-19 patients have the potential to affect these parameters, giving importance to these ECG markers may have a significant contribution in decreasing disease-related arrhythmias."],"journal":"Aging Male","authors":["Ozturk, Fatih","Karaduman, Medeni","Coldur, Rabia","Incecik, Saban","Gunes, Yilmaz","Tuncer, Mustafa"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32449420","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/13685538.2020.1769058","keywords":["covid-19","ecg","malignant arrhythmia","qt prolongation"],"topics":["Diagnosis"],"weight":1,"_version_":1667785214039949312,"score":50.67127},{"pmid":32260436,"pmcid":"PMC7180963","title":"Wearable Cardiorespiratory Monitoring Employing a Multimodal Digital Patch Stethoscope: Estimation of ECG, PEP, LVETand Respiration Using a 55 mm Single-Lead ECG and Phonocardiogram.","text":["Wearable Cardiorespiratory Monitoring Employing a Multimodal Digital Patch Stethoscope: Estimation of ECG, PEP, LVETand Respiration Using a 55 mm Single-Lead ECG and Phonocardiogram.","Cardiovascular diseases are the main cause of death worldwide, with sleep disordered breathing being a further aggravating factor. Respiratory illnesses are the third leading cause of death amongst the noncommunicable diseases. The current COVID-19 pandemic, however, also highlights the impact of communicable respiratory syndromes. In the clinical routine, prolonged postanesthetic respiratory instability worsens the patient outcome. Even though early and continuous, long-term cardiorespiratory monitoring has been proposed or even proven to be beneficial in several situations, implementations thereof are sparse. We employed our recently presented, multimodal patch stethoscope to estimate Einthoven electrocardiogram (ECG) Lead I and II from a single 55 mm ECG lead. Using the stethoscope and ECG subsystems, the pre-ejection period (PEP) and left ventricular ejection time (LVET) were estimated. ECG-derived respiration techniques were used in conjunction with a novel, phonocardiogram-derived respiration approach to extract respiratory parameters. Medical-grade references were the SOMNOmedics SOMNO HD(TM) and Osypka ICON-Core(TM). In a study including 10 healthy subjects, we analyzed the performances in the supine, lateral, and prone position. Einthoven I and II estimations yielded correlations exceeding 0.97. LVET and PEP estimation errors were 10% and 21%, respectively. Respiratory rates were estimated with mean absolute errors below 1.2 bpm, and the respiratory signal yielded a correlation of 0.66. We conclude that the estimation of ECG, PEP, LVET, and respiratory parameters is feasible using a wearable, multimodal acquisition device and encourage further research in multimodal signal fusion for respiratory signal estimation.","Sensors (Basel)","Klum, Michael","Urban, Mike","Tigges, Timo","Pielmus, Alexandru-Gabriel","Feldheiser, Aarne","Schmitt, Theresa","Orglmeister, Reinhold","32260436"],"abstract":["Cardiovascular diseases are the main cause of death worldwide, with sleep disordered breathing being a further aggravating factor. Respiratory illnesses are the third leading cause of death amongst the noncommunicable diseases. The current COVID-19 pandemic, however, also highlights the impact of communicable respiratory syndromes. In the clinical routine, prolonged postanesthetic respiratory instability worsens the patient outcome. Even though early and continuous, long-term cardiorespiratory monitoring has been proposed or even proven to be beneficial in several situations, implementations thereof are sparse. We employed our recently presented, multimodal patch stethoscope to estimate Einthoven electrocardiogram (ECG) Lead I and II from a single 55 mm ECG lead. Using the stethoscope and ECG subsystems, the pre-ejection period (PEP) and left ventricular ejection time (LVET) were estimated. ECG-derived respiration techniques were used in conjunction with a novel, phonocardiogram-derived respiration approach to extract respiratory parameters. Medical-grade references were the SOMNOmedics SOMNO HD(TM) and Osypka ICON-Core(TM). In a study including 10 healthy subjects, we analyzed the performances in the supine, lateral, and prone position. Einthoven I and II estimations yielded correlations exceeding 0.97. LVET and PEP estimation errors were 10% and 21%, respectively. Respiratory rates were estimated with mean absolute errors below 1.2 bpm, and the respiratory signal yielded a correlation of 0.66. We conclude that the estimation of ECG, PEP, LVET, and respiratory parameters is feasible using a wearable, multimodal acquisition device and encourage further research in multimodal signal fusion for respiratory signal estimation."],"journal":"Sensors (Basel)","authors":["Klum, Michael","Urban, Mike","Tigges, Timo","Pielmus, Alexandru-Gabriel","Feldheiser, Aarne","Schmitt, Theresa","Orglmeister, Reinhold"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32260436","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3390/s20072033","keywords":["ecg","ecg-derived respiration","lvet","pep","digital stethoscope","neural network","patch","phonocardiogram-derived respiration","respiration rate","wearable cardiorespiratory monitoring"],"topics":["Prevention"],"weight":1,"_version_":1666138491987165185,"score":41.303127}]}